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between lnTGF-b levels and age or BMI, and no signiﬁcant interactions
by race or gender were identiﬁed. No signiﬁcant differences were seen
for mean serum lnTGF-b levels by rOA status at the knee or the hip
in unadjusted or adjusted analyses (Table). There was a trend toward
increasing mean lnTGF-b with increasing severity at the knee in the
unadjusted analyses (p = 0.080) that was attenuated after adjustment
(p = 0.188). There was no association between lnTGF-b levels and unilat-
eral compared to bilateral knee or hip rOA in either unadjusted or adjusted
analyses.
Table: Least squared means of lnTGF-b by rOA outcome
Outcome Unadjusted
Mean
95%CI p value Adjusted
Mean
95%CI p value
HOA absent 2.80 2.76−2.85 0.713 2.80 2.76−2.85 0.862
HOA present 2.82 2.74−2.90 2.81 2.73−2.89
KOA absent 2.79 2.74−2.85 0.185 2.80 2.74−2.85 0.352
KOA present 2.84 2.79−2.89 2.83 2.78−2.88
KOA severity:
No KOA 2.79 2.74−2.85 n/a 2.79 2.74−2.85 n/a
Mild KOA 2.83 2.77−2.88 0.417* 2.82 2.76−2.88 0.505*
Mod/severe KOA 2.90 2.80−3.00 0.080* 2.88 2.77−2.99 0.188*
*p for comparison to no OA.
Conclusions: Although serum TGF-b was increased in AA compared
to Whites and in women compared to men, there were no signiﬁcant
associations with presence, laterality, or severity of knee or hip rOA,
suggesting that serum TGF-b is unlikely to be useful as a stand-alone
biomarker in OA studies.
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Purpose: Erosive osteoarthritis of the hand (EHOA) is thought to be an
aggressive variant of hand OA characterised by prominent local inﬂamma-
tion and radiographic aspects of bone erosions in interphalangeal joints.
Although serum levels of ultrasensitive CRP were found to be higher in
patients with EHOA in comparison with those with non-EHOA, biomarkers
have not been investigated until now in these patients.
Aims: (1) To determine Coll2−1, Coll2−1NO2 and myeloperoxydase
(MPO) levels in serum of patients with EHOA and compare these levels
with those of non-EHOA; (2) To investigate relationships between these
biomarkers and disease indices of severity and activity in EHOA.
Methods: Coll2−1, Coll2−1NO2 and MPO were measured in 82 patients,
62 with EHOA (57F and 5M, median age 59.5, range 41−74 years) and
20 with non-EHOA (all F, median age 55, range 43−73 years), fulﬁlling
ACR criteria for hand OA. EHOA was deﬁned in the presence of at least
one central bone erosion in the interphalangeal joints. Patients were also
evaluated for disease duration, number of affected (swollen or deformed)
joints, number of clinically active (swollen and painful or tender) (NCAJ),
radiographic score (RS), and number of active joints at bone scintigraphy
(NSAJ).
Results: Serum levels of Coll2−1NO2 and MPO were higher in patients
with EHOA (0.48±0.63 nM and 231.9±119.8 ng/ml, respectively) than in
those with non-EHOA (0.23±1.13 nM, p 0.067), although a signiﬁcance
was only reached by MPO (160.15± ng/ml, p< 0.043). No difference
was observed between the two groups for serum levels of Coll2−1. No
correlations were observed between the substances considered and the
other indices of disease activity or severity.
Conclusions: This is the ﬁrst study demonstrating an increase of
some serum biomarkers in EOA. In this context the most interesting
biomarker is MPO, although a trend for an elevation was also observed
for Coll2−1NO2.
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Purpose: The loss of cartilage matrix in osteoarthritis (OA) is character-
ized by increased loss of type II collagen and aggrecan by collagenases
and aggrecanases, respectively. Depletion of aggrecan is an early and an
important event in OA. We have observed ongoing aggrecanase activity
in late stage human osteoarthritic cartilage. Inhibition of aggrecanase
activity and upstream effectors may offer an attractive therapeutic target
for OA. Methods to detect and quantify aggrecanase activity for OA target
identiﬁcation/validation, screening of compounds, and to test activity
in biological/clinical samples is gaining great importance. A sensitive
aggrecanase ELISA has been developed to detect pM levels of both in-
vitro as well as cellular aggrecanase activities.
Methods: Either of two custom-made, C-terminal biotinylated, ‘aggre-
canase cleavage site’ (G373-374A) containing aggrecan interglobular do-
main (IGD) peptides (51/58mer) was used as the substrate. Samples
with or without inhibitors were added to the peptide-coated plate and
incubated. Cleaved aggrecan was detected by HRP-BC3 (anti-ARGS),
aggrecanase activity quantiﬁed, and IC50 determined. The assay was
also used to measure aggrecanase activity in synovial ﬂuid samples of
rats where the animals were oral dosed with drug and knee synovial ﬂuid
samples collected after intra-articular injection of aggrecanase. For the
cell-based assay format, primary bovine chodrocytes were cultured onto
peptide-coated plates followed by Il-1a induction with or without inhibitors.
Cellular activity was measured both in cell extracts and in conditioned
media to study the efﬁcacy of inhibitors.
Results: The in-vitro/cell-based 96-well format aggrecanase activity as-
say was found to be very selective and sensitive (detection range of
0.01−1 nM aggrecanase). IC50 values of aggrecanase inhibitors tested
in the ELISA were comparable to the FRET IC50s. The ELISA used
70−75 fold less enzyme than the FRET assay. IC50 determination was
not limited at low nM ranges in the ELISA as compared to the FRET
that could not determine IC50s below 30nM. The assay detected intra-
articularly injected aggrecanase activity in the diluted knee synovial ﬂuid
samples of rats dosed with drug and determined the inhibitory level
reﬂecting in-vivo drug efﬁcacy. In the cell-based assay format, primary
bovine chondrocytes produced aggrecanase activity upon Il-1 induction.
This activity was detected in the assay enabling a higher-throughput cell
based screening of aggrecanase inhibitors as compared to bovine explant
cultures.
Conclusions: The sensitive in-vitro/cellular aggrecanase activity ELISA
uses a longer IGD peptide of aggrecan that better represents the bio-
logical substrate as compared to the FRET peptide (10mer). This assay
is more sensitive as compared to the FRET and could determine IC50s
at low nM levels. The cell-based format of the assay would be useful for
chondrocyte-based secondary screening of aggrecanase inhibitors at a
higher throughput. This can also be extended to other purposes including
identiﬁcation/validation of OA targets (example: aggrecanase activity in
response to knockdown/over expression of potential OA targets in primary
human chondrocytes). Thus, the assay has the added advantage of
detecting cellular activity that would not be possible with the existing
commercial aggrecanase activity assays. The assay has been used
to monitor in-vivo drug efﬁcacy in animal models. The application of
this assay to detect activity in human synovial ﬂuids is currently being
evaluated.
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Purpose: To identify biochemical markers that predict OA progression.
Such prognostic biomarkers could provide valuable inclusion criteria for
clinical efﬁcacy trials to decrease the variability within patient populations
as well as to decrease the time required to detect a signiﬁcant change
in the outcome in response to treatment. We studied the relationship
between several biochemical markers and radiographic joint space nar-
rowing (JSN) (i.e., change in joint space width (JSW)) in OA patients over
2 years.
Methods: Urine, serum, and plasma samples were collected at 5 visits:
0, 3, 6, 12, and 24 months from healthy (n = 85) and OA human subjects
with symptomatic knee OA (n = 75). The diagnosis of OA was based on
a combination of pain or stiffness on most days of a month during the
past year and the presence of radiographic OA as deﬁned by Kellgren
and Lawrence grades (KLG) 0, 1, 2 and 3. Knee radiographs were
taken using the Lyon-Schuss protocol at 0 (baseline), 12, and 24 month.
Samples were analyzed for the levels of cartilage, bone, and synovium
matrix degradation and synthesis markers as well as for markers of
